Scioto Biosciences, Inc is a clinical stage biotech company founded in 2017, dedicated to pioneering research in the field of microbiome therapeutics. The company has developed a proprietary Activated Bacterial Therapeutics (ABT) platform for delivering top-tier live therapeutic bacteria to the gut. With a focus on the activation of beneficial bacteria, the company aims to advance healing for various diseases associated with the GI tract, Oncology, and CNS indications.
Scioto Biosciences operates in the Biotechnology and Health Care industries and is headquartered in the United States. Their most recent milestone is the $26.50M Series B investment secured on 10 August 2020, with Genome & Co. as the lead investor.
With its innovative approach and focus on leveraging the potential of live therapeutic bacteria, Scioto Biosciences is positioned to make significant contributions in addressing a wide range of medical challenges, making them an intriguing prospect for ventures interested in the forefront of biotech innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $26.50M | 1 | Genome & Co. | 10 Aug 2020 |
| Grant | $2.30M | 1 | National Institutes of Health | 22 Aug 2019 |
| Series A | $1.80M | 5 |
|
21 May 2018 |
| Grant | $330.00K | 1 | National Institutes of Health | 01 May 2017 |
| Grant | $25.00K | 1 |
|
01 Oct 2016 |
No recent news or press coverage available for Scioto Biosciences, Inc.
We care about your data, and we'd love to use cookies make your experience better.
